Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Melatonin Adjunct to Olanzapine for Prevention of Olanzapine-associated Metabolic Side Effects.

NCT01593774 is registered in ClinicalTrials.gov with Guilan University of Medical Sciences as lead sponsor.

NCT NCT01593774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01593774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Melatonin Adjunct to Olanzapine for Prevention of Olanzapine-associated Metabolic Side Effects.
Lead sponsor
Guilan University of Medical Sciences
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
March 31, 2013
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia